SEC Form 4 · accession 0001610717-26-000389
10x Genomics, Inc. · TXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shehnaaz Suliman
Director
Period of report
Aug 24, 2026
Accepted (ET)
Aug 26, 2026 · 4:42 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001770787
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Aug 24, 2026 | S | 561 | $62.7259 | D | 31,161 | D | |
| Class A Common StockF3 | Aug 24, 2026 | S | 1,646 | $63.9664 | D | 29,515 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.
- F2This transaction was executed in multiple trades at prices ranging from $62.26 to $63.23, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3This transaction was executed in multiple trades at prices ranging from $63.42 to $64.29, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.